Paolo Tarantino, 2025 Yvonne’s “Top Voice” Award Winner, Research Fellow at Dana-Farber Cancer Institute, Visiting Professor presso McGill University, shared a post on LinkedIn about a paper he co-authored with colleagues, published in Nature Reviews Cancer:
“ADCs and immune-checkpoint inhibitors: built to be combined?
Honored to cover this important topic during the ADC session of the 40th SITC conference in National Harbor, MD.
What the data tells us: several combinations of ADC/ICI have tremendous activity (SG/pembro, EV/pembro, Dato/Durva…) for multiple cancer types.
The open question: are they synergistic or additive? And does it matter what the mechanism is — if they ultimately prove able to extend OS and cure patients?
Some of the deepest discussions I’ve had on this topic were with Greg Thurber and Alfred ZIppelius, who also contributed to today’s session with great talks and chairing. The product of these discussions is now published on Nature Reviews Cancer.”
Title: Unveiling the molecular and immunological drivers of antibody–drug conjugates in cancer treatment
Authors: Alfred Zippelius, Sara M. Tolaney, Paolo Tarantino, Joseph P. Balthasar, Greg M. Thurber
Read The Full Article in Nature Reviews Cancer.
More posts featuring Paolo Tarantino on OncoDaily.